Thoracic Oncology
Research activity is centered on non-small cell lung cancer, with attention to molecularly defined disease and treatment needs in advanced lung cancer.
- NSCLC
- Thoracic malignancies
- Lung cancer
The sponsor’s clinical interest is directed toward patients with EGFR-mutated disease and other biologically distinct forms of non-small cell lung cancer.
Targeted Cancer Therapy
The funded research focuses on precision oncology approaches for tumors driven by specific resistance mechanisms, including mutation-selected treatment strategies.
- Targeted therapy
- Resistance mutations
- Oncogenic signaling
Clinical interest includes treatment options for C797S mutation-associated disease, reflecting a focus on molecularly defined cancer subgroups.
Biomarker-Defined Oncology
Research priorities include the use of genomic biomarkers to identify patients whose tumors carry actionable alterations relevant to treatment selection.
- Biomarker-driven care
- Genetic alterations
- Molecular profiling
This area supports study in mutation-positive lung cancer, where tumor biology guides therapeutic interest.
Anticancer Drug Development
The sponsor is engaged in clinical research around investigational oncology therapeutics intended for patients with advanced solid tumors, particularly within the respiratory oncology setting.
- Investigational therapy
- Solid tumor treatment
- Clinical oncology
Its funded work is aligned with treatment development for drug-resistant NSCLC populations.
